Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure)
Rheumatoid Arthritis
Pre-clinicalDevelopment (Partnership)
Key Facts
About LFB
The LFB Group is a leading French biopharmaceutical laboratory dedicated to providing healthcare professionals with critical medicinal products derived from plasma or recombinant proteins. Operating with a strong public health mission, it serves as an essential link between plasma donors and patients, developing and manufacturing biomedicines for serious, chronic, and rare diseases. With nearly 3,100 employees worldwide and sales of €599.6 million in 2024, LFB is a key player in ensuring therapeutic sovereignty in France while expanding its international footprint across Europe, the Americas, and other global markets.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| CORTONE (cortisone) | Merck | Commercial |
| Kevzara (sarilumab) | Regeneron Pharmaceuticals | Approved |
| Actemra (tocilizumab) | Chugai Pharmaceutical | Approved |
| Tocilizumab | Biocon | Filed |
| Humira | Abbott India | Approved |
| KPL-404 | Kiniksa Pharmaceuticals | Phase 2 |
| Tibulizumab (ZB-106) | Zura Bio | Phase 1b |
| Zunsemetinib (ATI-450) | Aclaris Therapeutics | Phase 2b |
| Natrunix Program | XBiotech | Not Specified |
| LEAPS Technology | CEL-SCI | Pre-clinical |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase 3 |